Eczema drug interaction study completed: what it means for patients
NCT ID NCT06686628
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how a new drug called amlitelimab affects the way the body processes other medications in adults with moderate-to-severe atopic dermatitis (eczema). 23 participants received amlitelimab and a cocktail of common drugs to measure changes in drug levels. The goal was to understand potential interactions, not to treat the disease itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 2760001
Berlin, 10117, Germany